Drug Repurposing Market Report Scope & Overview:

Drug Repurposing Market was valued at USD 34.79 billion in 2025 and is expected to reach USD 50.91 billion by 2035, growing at a CAGR of 3.93% from 2026-2035. 

The Drug Repurposing Market is witnessing steady growth because of the rise in demand for efficient and effective ways to develop medications. Repurposing existing medicines for other therapeutic uses may cut down the time and expenses related to traditional drug discovery along with certain risks. There has been increased interest in developing medicines for treating rare diseases, unmet medical needs, and new infections, which is further promoting the acceptance of this trend. Moreover, progress in the areas of artificial intelligence, drug screening, molecular databases, and analytics has led to improved discovery of possibilities in repurposing drugs.

NIH's National Center for Advancing Translational Sciences supports computational and data-driven approaches to accelerate therapeutic development and identify new uses for existing medicines.

Drug Repurposing Market Trends

• Rising demand for faster and cost-effective drug development is driving adoption of repurposing strategies for existing approved and investigational medicines.

• Increasing prevalence of rare, chronic, and emerging diseases is encouraging researchers to identify alternative therapeutic applications for established drugs.

• Growing adoption of artificial intelligence and machine learning is accelerating drug repurposing by analyzing biological, clinical, and molecular datasets.

• Increasing availability of genomic, proteomic, and real-world evidence is improving identification of potential drug-disease associations and therapeutic opportunities.

• Rising pharmaceutical research costs and lengthy development timelines are encouraging companies to leverage existing safety and pharmacological data for new indications.

The U.S. Drug Repurposing Market Outlook

U.S. Drug Repurposing Market was valued at USD 12.35 billion in 2025 and is expected to reach USD 17.98 billion by 2035, growing at a CAGR of 3.88% from 2026-2035. 

The U.S. Drug Repurposing Market is witnessing steady growth as a result of increasing need for efficient drug development methodologies that are not only cost but also time effective. The use of already existing drugs for new purposes will help save time and money on development process as well as minimize some risks associated with development of novel drugs. The increasing interest in rare diseases, unmet medical needs, and newly emerging infectious diseases further contributes to the adoption of drug repurposing. The development of technologies like artificial intelligence, drug screening and analysis via computer modeling, and molecular databases facilitates the identification of drug repurposing opportunities.

In May 2026, the FDA specifically expanded its focus on drug repurposing for chronic and rare diseases, strengthening the regulatory and institutional environment for repurposed therapies.

Drug Repurposing Market Segment Analysis  

• By Drug Type, Small Molecules dominate the Drug Repurposing Market with 67% share in 2025; Biologics are expected to grow at the fastest CAGR of 4.39% from 2026–2035.

• By Therapeutic Area, Oncology dominates the Drug Repurposing Market with 28% share in 2025; Neurology and CNS Disorders are expected to grow at the fastest CAGR of 5.58% from 2026–2035.

• By Route of Administration, Oral dominates the Drug Repurposing Market with 55% share in 2025; Intravenous is expected to grow at the fastest CAGR of 4.64% from 2026–2035.

• By End Use, Pharmaceutical and Biopharmaceutical Companies dominate the Drug Repurposing Market with 58% share in 2025; Contract Research Organizations (CROs) are expected to grow at the fastest CAGR of 4.71% from 2026–2035.

By Drug Type, Small Molecules dominates the drug repurposing market, Biologics grows fastest.

Small Molecules segment dominated the Drug Repurposing Market with the highest revenue share of about 67% in 2025 due to their proven safety profile, large volume of clinical data, and availability across all medical fields. Being relatively simple in structure, having a known pharmacology make them easy to identify for new applications. Simplicity of their development process, existing manufacturing facilities, and abundant history make them suitable for repurposing worldwide.

Biologics segment is expected to grow at the fastest CAGR of 4.39% from 2026-2035 due to increased interest in repositioning antibodies, recombinant proteins, and other biologics for other purposes. Information from clinical trials and safety studies may help make development easier. The growing need for treatment specificity, advances in biologics characterization, and increased spending on innovative drug uses will likely speed up biologic repositioning.

By Therapeutic Area, Oncology dominates the drug repurposing market, Neurology and CNS Disorders grows fastest.

Oncology segment dominated the Drug Repurposing Market with the highest revenue share of about 28% in 2025 because of high research activity, high medical needs, and availability of drugs with known pharmacodynamics. Repurposing allows finding new anti-cancer uses as well as lowering the time of development process. Rising cancer cases, increasing clinical research, and need for efficient medicine makes the repurposing for oncology even more attractive.

Neurology and CNS Disorders segment is expected to grow at the fastest CAGR of 5.58% from 2026-2035 due to high treatment gaps and complicated disease mechanisms that necessitate novel treatment strategies. Repurposing of existing drugs provides avenues for speeding up the discovery of treatments for neurological disorders. Research on neurodegenerative disorders, increase in disease burden, and advances in computational drug discovery are anticipated to propel repurposing efforts.

By Route of Administration, Oral dominates the drug repurposing market, Intravenous grows fastest.

Oral segment dominated the Drug Repurposing Market with the highest revenue share of about 55% in 2025 Due to convenience, patient compliance, existing drug formulation techniques, and widespread availability of oral medications. Oral medications can be distributed and administered in different health care setups conveniently. Existing experience in clinical settings and widespread therapeutic application is another reason for using oral medication for repurposing.

Intravenous segment is expected to grow at the fastest CAGR of 4.64% from 2026-2035 due to increased repurposing of biologics and drugs that need to be administered in a controlled manner systemically. Intravenous drug delivery offers fast and reliable distribution of the drug within the body, making it useful in treating complicated diseases. An increase in hospital treatments, oncological use, and targeted therapy will drive intravenous drug repurposing.

By End Use, Pharmaceutical and Biopharmaceutical Companies dominate the drug repurposing market, Contract Research Organizations (CROs) grow fastest.

Pharmaceutical and Biopharmaceutical Companies segment dominated the Drug Repurposing Market with the highest revenue share of about 58% in 2025 Because of their drug libraries, clinical research abilities, knowledge of regulations, and money. They can effectively screen drugs for other applications. More emphasis being put on minimizing development costs and time frames makes it even more likely for pharmaceuticals to repurpose drugs.

Contract Research Organizations (CROs) segment is expected to grow at the fastest CAGR of 4.71% from 2026-2035 due to rising outsourcing of pharmaceutical discovery, clinical trials, data analyses, and regulation activities. CROs have expertise and resources that can aid companies to cut development expenses and time. Increased complexity in repurposing initiatives along with increased collaboration between the developers and the research organizations will drive CRO demand further.

Regional Analysis

North America Drug Repurposing Market Insights 

North America dominated the Drug Repurposing Market with the highest market share of about 39% in 2025, This region is driven by strong R&D capabilities in pharmaceuticals, well-developed health care infrastructure, and clinical trials. This is a market-driven region owing to large presence of pharmaceutical and biotechnology firms, positive regulation policies, and development of drug discovery ecosystems powered by artificial intelligence.

The U.S. Drug Repurposing Market accounted for a market share of 88.5%, backed up by its highly evolved pharmaceutical industry, robust clinical research skills, and substantial funding of drug discovery. Repurposing is fueled by an increasing number of artificial intelligence and computational systems, existing regulatory pathways, and requirements for time and cost-effective drug development. High level of cooperation between pharmaceutical companies, biotechnology companies, and academic centers adds to this advantage.

Europe Drug Repurposing Market Insights

Europe Drug Repurposing Market has been showing continuous growth through its well-equipped pharmaceutical research and established academic facilities, and various European Union-supported programs that concentrate on the identification of new applications for the currently available drugs. Programs like REPO4EU and REMEDi4ALL are improving collaboration, artificial intelligence-based drug discovery, and validation. Other factors, such as regulatory support, unmet medical needs, and reduced development costs and timeframes, also promote the regional market.

The Germany Drug Repurposing Market accounted for a market share of 31.0%, Due to the robust pharmaceutical and biotech industry, excellent research and development setup, and significant capacity for academic research. Increased collaborations between pharma companies and research organizations are aiding in the recognition of new areas for therapeutic use. Translational medicine and computational drug discovery are contributing to making Germany a strong player in Europe.

Asia Pacific Drug Repurposing Market Insights

Asia Pacific is expected to grow at the fastest CAGR of about 5.02% from 2026–2035, Backed up by growing pharmaceuticals and biotech industries, spending on healthcare, and research abilities. Growth in clinical trials, government funding for life sciences, the presence of skilled researchers, increased use of computational drug discovery, and interest in developing cost-effective therapeutics are driving the regional market further ahead.

The China Drug Repurposing Market accounted for a market share of 39.0%, Backed by increased capacity in pharmaceutical R&D, increased clinical research, and the use of computational biology and artificial intelligence. Investment in healthcare infrastructure and innovations in drugs within the country are driving the repurposing efforts. Government promotion of pharmaceutical innovation and collaboration between local and foreign institutions are adding to the market development of China.

Middle East & Africa and Latin America Drug Repurposing Market Insights

The Middle East & Africa and Latin America Drug Repurposing Market is gradually expanding, Fuelled by growing health care investment, unmet medical needs, and interest in cost-effective treatment. The ability to conduct advanced research in pharmaceuticals and enhance the healthcare system is leading to possibilities of repositioning existing drugs. Healthcare programs by government, academia–industry collaboration, regulation, and the emphasis on rapid treatment access add up to support regional market growth.

The UAE Drug Repurposing Market accounted for a market share of 15.0%, facilitated by better health care infrastructure, increased investments in pharmaceuticals, and rising demand for cost-effective ways to develop therapies. Enhanced research capacities and healthcare improvements are providing opportunities for drug repurposing. Health care programs, research collaborations, and increased attention to meeting unmet medical needs by governments are contributing to market growth in the UAE.

Market Dynamics

Growth Drivers: Increasing need to reduce drug development time and costs is accelerating adoption of drug repurposing strategies globally

The increasing cost, complexity, and lengthy timelines associated with conventional drug development are significantly driving demand for drug repurposing. Repurposing refers to the identification of new uses or target populations for drugs already in existence so that companies can take advantage of safety, pharmacology, manufacturing and clinical information which have been generated from these drugs. According to the FDA, one way that repurposing helps to accelerate treatment is through the utilization of proven safety profile, manufacturing capabilities, and clinical experience that is associated with a drug. Repurposing can result in the reduction of some steps of drug development compared with the development of entirely new drugs.

Restraints: Limited intellectual property protection and commercial incentives can restrict investment in repurposed drug development

Limited intellectual property protection can represent a significant challenge for companies investing in drug repurposing. These existing drugs could have expired or their patents may be under threat and it would therefore not be easy for a developer to gain sufficient commercial exclusivity in cases where an indication is discovered. This could lower the incentive for financing clinical studies and commercialization. The FDA has identified a number of drugs for potential repurposing where scientific data may be present but commercial incentive for approval may be lacking. It would thus be necessary for a developer to rely on regulatory incentives and/or other forms of commercialization to achieve a commercial business model.

Opportunities: Rapid integration of artificial intelligence and machine learning is creating significant opportunities for data-driven drug repurposing globally

The integration of artificial intelligence, machine learning, natural language processing, biomedical knowledge graphs, and computational biology is creating substantial opportunities for drug repurposing. These AI-based systems can analyze huge amounts of data related to genomics, clinical trials, molecules, scientific literature, and drugs interactions in order to find correlations between already existing drugs and novel targets for diseases. There is a rapid growth of AI in the drug repurposing market, which is explained by the rising number of investments in the computational methods and collaboration between pharmaceutical firms and artificial intelligence technology companies. In addition, the latest trends in the industry indicate an increased application of AI and automated labs in pharmaceutical research.

Recent Developments:

• 2026 : Every Cure continued expanding its AI-driven drug repurposing platform, using large-scale biomedical data and artificial intelligence to identify and advance existing medicines for diseases with significant unmet medical needs.

• 2026 : REMEDi4ALL continued advancing international drug-repurposing programs focused on rare diseases, cancers, and infectious diseases, while strengthening collaboration among researchers, patients, regulators, and industry stakeholders.

• 2026 : Recursion Pharmaceuticals continued advancing AI-enabled drug discovery and repurposing by integrating large-scale biological datasets, automated experimentation, and computational models to identify potential therapeutic opportunities more efficiently.

• 2025 : Every Cure developed its AI-enabled end-to-end drug repurposing platform to systematically identify, evaluate, and advance existing medicines for new therapeutic indications, supporting faster identification of treatments for unmet medical needs.

Drug Repurposing Market key players are:

• AbbVie Inc.

• Amgen Inc.

• Boehringer Ingelheim International GmbH

• Eli Lilly and Company

• GSK plc

• Novartis AG

• Pfizer Inc.

• Sanofi S.A.

• AstraZeneca plc

• Johnson & Johnson

• Takeda Pharmaceutical Company Limited

• Bristol Myers Squibb Company

• Roche Holding AG

• Biogen Inc.

• Recursion Pharmaceuticals, Inc.

• Evotec SE

• Melior Discovery, Inc.

• SOM Biotech S.L.

• Every Cure

• NovaLead Pharma Pvt. Ltd

Drug Repurposing Market Report Scope: